Metabolomics profiling for identification of novel potential markers in early prediction of preeclampsia. by Kuc, S. et al.
Metabolomics Profiling for Identification of Novel
Potential Markers in Early Prediction of Preeclampsia
Sylwia Kuc1*, Maria P. H. Koster1, Jeroen L. A. Pennings2, Thomas Hankemeier3,4, Ruud Berger3,4,
Amy C. Harms4, Adrie D. Dane4, Peter C. J. I. Schielen5, Gerard H. A. Visser1, Rob J. Vreeken3,4
1Department of Obstetrics, Wilhelmina Children’s Hospital, University Medical Centre Utrecht (UMCU), Utrecht, the Netherlands, 2 Laboratory for Health Protection
Research (GBO), National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands, 3 Leiden Academic Center for Drug Research, Division of
Analytical Biosciences, Leiden University, Leiden, The Netherlands, 4 The Netherlands Metabolomics Centre, Leiden University, Leiden, the Netherlands, 5 Laboratory for
Infectious Diseases and Perinatal Screening (LIS), National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
Abstract
Objective: The first aim was to investigate specific signature patterns of metabolites that are significantly altered in first-
trimester serum of women who subsequently developed preeclampsia (PE) compared to healthy pregnancies. The second
aim of this study was to examine the predictive performance of the selected metabolites for both early onset [EO-PE] and
late onset PE [LO-PE].
Methods: This was a case-control study of maternal serum samples collected between 8+0 and 13+6 weeks of gestation
from 167 women who subsequently developed EO-PE n= 68; LO-PE n = 99 and 500 controls with uncomplicated
pregnancies. Metabolomics profiling analysis was performed using two methods. One has been optimized to target
eicosanoids/oxylipins, which are known inflammation markers and the other targets compounds containing a primary or
secondary biogenic amine group. Logistic regression analyses were performed to predict the development of PE using
metabolites alone and in combination with first trimester mean arterial pressure (MAP) measurements.
Results: Two metabolites were significantly different between EO-PE and controls (taurine and asparagine) and one in case
of LO-PE (glycylglycine). Taurine appeared the most discriminative biomarker and in combination with MAP predicted EO-PE
with a detection rate (DR) of 55%, at a false-positive rate (FPR) of 10%.
Conclusion: Our findings suggest a potential role of taurine in both PE pathophysiology and first trimester screening for EO-
PE.
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Introduction
Preeclampsia (PE) remains a leading complication of pregnancy
and affects approximately 2% of women worldwide [1–3]. Early
onset PE (EO-PE), requiring delivery before 34 weeks of gestation
(GA), is considered the most severe form of the disease in contrast
to late onset PE (LO-PE; delivery $34 weeks GA) [3;4]. Apart
from perinatal problems, PE is also associated with substantial
health problems later in life. Both women who suffered from PE
and their children have a substantially elevated risk of chronic
hypertension, cardiovascular disease and diabetes mellitus type-2
[5]. The diagnosis of PE is based on clinical symptoms, such as
proteinuria and de novo hypertension. These symptoms however
are only the terminal features of a cascade of events initiated
during the first trimester of pregnancy [6;7]. Therefore early
recognition of patients at high risk and timely intervention ahead
of the clinical onset of the disease would enable suitable pregnancy
care and hopefully better pregnancy outcomes for both mother
and child.
It becomes more and more clear that PE is caused by
interactions between complex pathophysiological mechanisms,
individual genes and environmental factors. Some features of the
pathophysiology of PE have been elucidated already. Underlying
mechanisms comprise impaired early placentation and trophoblast
invasion in the spiral arteries, placental hypoxia and endothelial
dysfunction [8–11]. However, there is currently no complete view
on the pathophysiology of PE. Classical approaches to discover
novel PE biomarkers are hypothesis-driven and concentrate
mostly on the early placental development and maternal
adaptation to pregnancy. Other approaches which include novel
classes of methods, such as ‘‘omics technologies’’ are ‘‘integrated
system-based’’ methods which study general chemical processes in
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the whole organism to subsequently focus on differences in
concentrations of individual molecules, their interactions and role
in the pathogenesis.
One of these ‘‘omics’’ technologies is metabolomics. Metabo-
lomics has been successfully applied as biomarker discovery tool
for the early detection of diseases such as cancer and cardiovas-
cular disease [12].
Early prediction of PE by using metabolomics analyses on
samples derived from maternal blood has been investigated by
other groups (Table 1) [13–16]. The markers identified differ
between studies as do the detection rates, and ranged from 50% in
a heterogeneous PE group to 82.6% in an EO-PE group when
metabolites are combined with classical PE screening markers such
as maternal characteristics, uterine artery Doppler velocity and
fetal crown-rump-length (CRL) measurements [13–16].
In our large nested case-control study we have divided the PE
group in two subgroups (EO-PE and LO-PE), as it is known that
PE is a heterogeneous syndrome and the pathophysiology of both
entities may differ [9;17;18]. In order to cover the biologically
relevant pathways, we selected two metabolomics profiling
methods. One has been optimized to target eicosanoids/oxylipins,
which are know inflammation markers and the second method
targets a wide variety of biogenic amines, including the amino
acids.
These groups of metabolites are associated with PE as well other
pregnancy complications such as placental abruption, IUGR and
preterm birth [19–23]. Furthermore both groups are also strongly
associated with different inflammatory processes in the cell and
endothelial dysfunctions, which are common for PE and
cardiovascular disease later in life [24–26]. The above associations
make them potentially suitable candidate markers for prediction of
PE.
The study had two aims: the first aim was to investigate specific
signature patterns of metabolites that are significantly altered in
first-trimester serum of women who subsequently developed PE
compared to healthy pregnancies. The second aim of this study
was to examine the predictive performance of the selected
metabolites for both EO-PE and LO-PE.
Material and Methods
Ethics Statement
This study approach was approved by the Scientific Ethical
Committee of the University Medical Centre of Utrecht (METC
Utrecht), the Netherlands (protocol number: 11-002). All partic-
ipating women in this manuscript have given written informed
consent during the first-trimester Down syndrome screening.
Study population
This was a nested case-control study derived from a large cohort
of women participating in the routine Dutch first trimester Down
syndrome screening between 2007 and 2009. In this context
maternal age, sample date, gestational age (GA) at sampling,
maternal weight, method of conception, history of diabetes, and
smoking status were recorded by a midwife or gynaecologist. As
part of the screening, maternal serum concentrations of two
standard placental markers (pregnancy-associated plasma protein-
A [PAPP-A] and free b-subunit of human Chorionic Gonadotro-
pin [fb-hCG]) were measured in serum of blood sampled at 8+0–
13+6 weeks GA. After blood withdrawal, samples were centrifuged
within 6 hours and stored at 4uC until serum analysis for PAPP-A
and fb-hCG. Subsequently, serum samples were stored at 280uC
until metabolomics analysis. Thus, samples underwent one freeze-
thaw cycle prior to analysis. All samples used in this study were
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handled the same way. Where applicable, GA was calculated
based on first trimester CRL measurement at ultrasound
examination using the formula of Robinson and Fleming (1975)
[27]; otherwise the first day of the last menstrual period was used.
Pregnancy outcomes, including chromosomal disorders, date of
birth, birthweight and hypertensive pregnancy complications (PE,
HELLP syndrome or pregnancy induced hypertension), were
collected through self-reporting by the participating women. Six
months after the estimated delivery date, a reminder letter was
sent to these women to collect missing data. This way, 75% of all
pregnancy outcomes could be recorded. For the current study
women with a multiple pregnancy, women who delivered before
24 weeks and women who gave birth to a child with a
chromosomal abnormality were excluded.
By follow up of self-reported cases of EO-PE we confirmed the
diagnosis of EO-PE in 68 pregnancies at the participating
hospitals. Moreover, from a larger cohort of women who
developed LO-PE we randomly selected 99 cases. From all EO-
PE and LO-PE cases we collected missing data on maternal
characteristics i.e. medical history, parity, weight, height, first
trimester mean arterial pressure (MAP) and pregnancy outcome
i.e. GA at delivery, birthweight and fetal sex. The control group,
consisting of 500 women having delivered phenotypically and
chromosomally normal neonates at term (37+0–42+0 weeks) and
not having developed any pregnancy complication, was randomly
selected from the two largest ultrasound centres participating in
the routine Dutch first trimester Down syndrome screening
program (Universitair Verloskundig Centrum Utrecht and De
Poort Leiden). The outcomes of these pregnancies were confirmed
in the midwifery practices and missing maternal characteristics
and first trimester MAP were collected.
Outcome measures
PE was defined according to the criteria of the International
Society for the Study of Hypertension in Pregnancy as: gestational
hypertension beyond 20 weeks GA in previously normotensive
women with a systolic blood pressure $140 mm Hg and/or
diastolic blood pressure $90 mm Hg on at least two occasions
four hours apart, with the presence of proteinuria of $300 mg in
24-hour collection or at least 2+ by dipstick on a spot urinalysis
[6]. Early onset PE (EO-PE) was defined as PE in pregnancies
delivering ,34 weeks GA, and late onset PE (LO-PE) as PE in
pregnancies delivering $34 weeks. Pregnancy at term was defined
as delivery $37 weeks of GA.
MAP was calculated from the formula DP+1/3 (SP – DP),
where DP represents diastolic blood pressure and SP -systolic
blood pressure.
Sample analysis
Amine measurements were performed using the method based
described previously by Noga et al., 2012 [28]. The amine
platform covers amino acids and biogenic amines employing an
Accq-tag derivatization strategy adapted from the protocol
supplied by Waters (Etten-Leur, The Netherlands). 5 mL of each
plasma sample was spiked with an internal standard solution,
followed by deproteination by addition of MeOH. The superna-
tant was transferred to a deactivated autosampler vial (Waters) and
dried under N2. The residue was reconstituted in borate buffer
(pH 8.5) with 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate
(AQC) reagent (Waters). After reaction, the vials were transferred
to an autosampler tray and cooled to 10uC until the injection
(1.0 mL) of the reaction mixture into the UPLC-MS/MS system.
An ACQUITY UPLC system with autosampler (Waters) was
coupled online with a Xevo Tandem Quadrupole mass spectrom-
eter (Waters) operated using Masslynx data acquisition software
(version 4.1; Waters). The samples were analyzed by UPLC-MS/
MS using an Accq-Tag Ultra column (Waters).
The Xevo TQ was used in the positive-ion electrospray mode
and all metabolites were monitored in Selective Reaction
Monitoring (SRM) using nominal mass resolution.
Acquired data were evaluated using Quanlynx software
(Waters), by integration of assigned SRM peaks and normalization
using proper internal standards. For analysis of amino acids their
13C15N-labeled analogs were used. For other amines, the closest-
eluting internal standard was employed. Blank samples were used
to correct for background, and in-house developed algorithms
were applied using the pooled QC samples to compensate for drift
in the sensitivity of the mass spectrometer with and over different
batches [29].
Measurements of eicosanoids/oxylipins was performed as
described earlier by Strassburg et al [30]. After thawing the
250 mL serum aliquots on ice, the samples were treated
immediately with antioxidants (0.2 mg 3,5-di-t-butyl-4-hydroxy-
toluene [BHT]/Ethylenediaminetetraacetic acid [EDTA]) and
spiked with a set of 34 isotopically labeled internal standards
(ISTDs). Compound extraction was performed with solid phase
extraction using Oasis Hydrophilic-lipophilic-balanced reversed-
phase sorbent for acids [HLB] (60 mg/30 mm). Oxylipins were
eluted with 2 mL ethyl acetate after wetting the cartridge with
0.5 mL methanol. The eluent was reduced under nitrogen. The
dried extract was subsequently reconstituted in 50 mL solution of
methanol and acetonitrile (1:1) containing 100 nM 1-cyclohex-
yluriedo-3-dodecanoic acid (CUDA) as a quality marker for the
analysis. Afterwards, the extract was filtered by centrifugation
using Amicon Ultrafree-MC Durapore PVDF filter (pore-size
0.1 mM; Millipore, Bedford, MA).
Samples were analyzed by liquid chromatography (LC-MS;
Agilent 1260, San Jose, CA, USA) coupled to electrospray
ionization on a triple quadrupole mass spectrometer (Agilent
6460, San Jose, CA, USA). For analysis 5 mL of the extract was
injected. The auto sampler was cooled at 10uC. Chromatographic
separation was achieved on an Ascentis Express (2.16150 mm,
2.7 mm particles; Sigma-Aldrich Supelco) column using the
solvents A, 0.1% acetic acid, and B, 90:10 v/v acetonitril/
isopropanol. Electrospray ionization was performed in the
negative ion mode.
To detect the individual oxylipins, MRM in negative ion mode
was performed with individually optimized fragmentor voltage
and collision energies (Optimizer application, MassHunter,
Agilent). Optimal MRM settings were obtained from flow
injection analysis of pure standards using the optimizer application
and compared to literature when available. Dynamic MRM was
used, assuring optimal dwell time and sufficient data points per
peak.
Peak determination and peak area integration was performed
automatically with MassHunter Quant (Agilent, Version B.04.00)
while auto-integration was manually inspected and corrected if
necessary. The obtained peak areas of targets were corrected by
appropriate ISTD and calculated response ratios were used
throughout the analysis. In-house developed algorithms were
applied using the pooled QC samples to compensate for shifts in
the sensitivity of the mass spectrometer over different batches [29].
Statistical analysis
Only metabolites detected in more than 80% of the samples
were included in statistical analysis. For other analytes, data below
the detection limit, where the LC-MS software provided a missing
value, were imputed as half the lowest detectable value for that
Metabolomics for the Prediction of Preeclampsia
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individual analyte. This replacement was made to get a more
realistic value in further calculations and was a compromise
between substituting a zero value, which would be an underes-
timation, and truncating these values at the lowest measurable
level, which would be an overestimation of their actual concen-
trations.
In accordance with the statistical approach described below, the
data set was divided into sets for training, testing (evaluation) and
validation, respectively. For each group (controls, EO-PE, LO-
PE), samples were randomly assigned to the training (40%), test
(30%) or validation set (30%). Overall samples assignment was as
follows: training set 200 controls, 27 EO-PE, 40 LO-PE; test set
150 controls, 20 EO-PE, 30 LO-PE; validation set 150 controls, 21
EO-PE, 29 LO-PE.
After this random assignment we confirmed that there were no
significant differences in maternal characteristics between the
three sets (results not shown). The concentration of the (remaining)
metabolites and MAP of the training set were expressed as
multiples of the gestation-specific normal medians (MoMs). MoMs
were log-transformed to provide normal distributions. Normal
medians were obtained by regression analysis of the median
concentration for each completed gestational week in the controls
of the training set, weighted for the number of women tested.
Values of MoM were adjusted for variables such as gestation,
weight, smoking and ethnicity where MoM values differed
significantly between groups (within controls), following the
standard methods described by Cuckle and Wald, with curve
fitting based on the training set [31].
Maternal characteristics (i.e. medical records, parity, weight and
length) were used to calculate prior risks for PE in multiple logistic
regression models. The steps undertaken to develop the models for
prior risk for EO-PE and LO-PE were described earlier in detail in
our recent article [32].
In the next step, metabolites MoM data were compared
between controls and either EO-PE or LO-PE, using a Student’s t-
test. Values were corrected for multiple testing by calculating the
False Discovery Rate (FDR).
The potential of MAP and metabolites with FDR,15% as part
of a PE prediction model was further tested using logistic
regression in R statistical software. Training models were based
on training set data (controls and either EO-PE or LO-PE cases)
for prior risks and log-MoM data for each significant metabolite as
well as all possible metabolites combinations. Models were then
tested on test set data for the corresponding metabolites. Models
were evaluated based on their predicted Detection Rate [DR]
(sensitivity) in the test set for a fixed 10% False Positive Rate [FPR]
(1-specificity).
The final models of risk prediction including the metabolite
values were calculated in R using separate models for both EO-PE
and LO-PE, respectively. The model with the best performance
was validated on the validation set.
Since we previously found that PE pregnancies complicated by
growth restriction (,10th birth weight centile), had more
distinctive classical marker levels that PE alone, both prediction
models (EO-PE and LO-PE) were separately examined for both
neonates that were appropriate-for-gestational age (AGA) and
those who had a birth weight below the 10th centile [32].
Statistical analyses were performed using SPSS (release 20.0;
Chicago, IL), SAS software package (release 9.2; SAS Institute,
Cary, NC, USA) and R programming language version 2.15
(http://www.r-project.org).
Results
Baseline characteristics of the study population are shown in
Table 2. Women who developed PE had higher BMI (EO-PE 24.7,
p,0.0001; LO-PE 23.7, p= 0.005), were more often smokers
(EO-PE 11.8% vs 4.2%, p= 0.008), and more often had a history
of hypertensive pregnancy disorders compared to controls (EO-PE
5.9%, p= 0.009; LO-PE 10.1%, p,0.0001). Furthermore, there
were more nulliparous women among the cases (both EO-PE
80.9% and LO-PE 72.7%, p,0.0001).
Table 2. Adapted from Kuc et al., 2013 – Study population baseline characteristics in control and PE pregnancies. Values are
presented as median (IQR) or number (%) [32].
Characteristics Controls EO-PE LO-PE
n=500 n=68 n=99
Maternal age (y) 33 (30–35) 34 (30–37) 33 (30–36)
Maternal weight (kg) 65.5 (60.0–73.0) 70.0 (62.0–81.5)* 67.5 (62.0–75.0)
Maternal BMI (kg/m2) 22.8 (20.7–24.8) 24.7 (21.9–29.3)* 23.7 (21.3–26.5)*
Nulliparity 233 (46.6) 55 (80.9)* 72 (72.7)*
Smoking 21 (4.2) 8 (11.8)* 6 (6.1)
Assisted reproduction 0 (0) 3 (4.4) 8 (8.1)
Gestation at sampling (days) 88 (84–91) 85 (76–89)* 85 (79–89)*
History of hypertensive pregnancy disorders 4 (0.8) 4 (5.9)* 10 (10.1)*
Gestation at birth (wk) 40 (39–41) 31 (30–32)* 37 (36–39)*
Birthweight (gr) 3544 (3243–3800) 1300 (1045–1609)* 2650 (2130–3110)*
Birthweight centile 57.0 (33.1–78.4) 25.0 (13.4–50.4)* 13.8 (3.8–46.0)*
Sex, n male (%) 244 (48.8) 34 (49.7) 53 (53.5)
A Pearson’s chi square test and Mann-Whitney U test, both with post hoc Bonferroni correction were used for statistical analysis. Adjusted significance value p,0.016 (*).
EO-PE: early-onset preeclampsia; LO-PE: late-onset preeclampsia; IQR: interquartile range; BMI: body mass index.
doi:10.1371/journal.pone.0098540.t002
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Metabolite pre-selection
Using the data in the training set, we analyzed a total number of
105 potential variables (58 amines, 46 oxylipins and MAP) for
statistically significantly different levels between controls and cases
of both EO-PE and LO-PE. MAP proved significant for both of
these comparisons, with a 10% (MoM ratio case and controls
[MoMR]= 1.10) and 7% (MoMR 1.07) increase in EO- and LO-
PE, respectively, and both p-values less than 1024 (Table 3). For
the amines, taurine and asparagine were significantly different
(FDR,15%) between EO-PE and controls, with approximately
20% reduced levels (MoMR 0.79 and 0.84, respectively).
Glycylglycine showed a significant reduction in LO-PE of 28%,
MoMR 0.72 (Table 3). None of the oxylipins showed a significant
(FDR 15%) difference for any group.
Model selection
Prediction models were fitted based on the training set, using
the prior risk and one or more of the significant markers. For EO-
PE the model prediction rule was: 1/(1+e‘-(22.999+33.491 x
MAP-MoM 22.490 x Taurine)). For LO-PE the model prediction
rule was: 1/(1+e‘-(21.9792+22.0164 x MAP-MoM 22.490 x
Taurine)).
Comparison of the performance of these models on the test set
indicated that for EO-PE the highest DR was obtained for the
model with prior risk, MAP and taurine. This model gave a DR of
88% at a FPR of 10%, which is a 19% gain on the DR obtained
using only the prior risk. We selected this model for further
validation. Another model using prior risk, MAP, taurine and
asparagine also gave a DR of 88% (Table 4). However, this latter
model was not selected, as adding asparagine to the model did not
result in further improvement of the DR as compared to the
former model.
For LO-PE, the best predicting model included prior risk and
MAP. This model did not include any metabolites (Table 4).
Validation
Applying the selected models to independent data validated the
EO-PE model. This model gave a DR of 55%, which was a 25%
improvement to the DR obtained using only the prior risk
(Table 4). This gain of 25% was also obtained for the training set.
The LO-PE model resulted in a DR of 17% (Table 4). Neither
metabolic marker nor MAP improved this model. Final models for
both EO-PE and LO-PE are shown in Figure 1. Additionally both
models (EO-PE and LO-PE) were separately examined for
growth-restricted fetuses. None of the metabolites showed any
improvement in DR in these particular subgroups.
Discussion
Early detection of PE would allow the development and
application of targeted intervention. Detection, however, has been
restricted to clinical parameters such as high blood pressure and
presence of protein in the urine until recently. When these
parameters are present, the condition has already progressed. An
assay-detecting women at risk to develop PE at an early stage
would therefore be extremely helpful in preventing its severe
symptoms at the end of the pregnancy. To be able to develop such
an effective first trimester prenatal screening test, sets of
biomarkers are needed that are capable of detecting the presence
of pathologic conditions in maternal serum with high sensitivity
and specificity.
In this study we applied LC-MS based metabolomics to assess
the diagnostic potency of metabolites such as amines and oxylipins
to predict EO-PE en LO-PE from first trimester maternal serum.
Using standardized metabolomics analytical techniques and an
established statistical approach we identified two molecules of
which the serum concentrations were significantly decreased in the
first trimester maternal serum of women who subsequently
develop EO-PE, and one metabolite with decreased levels in
LO-PE compared to controls. All three compounds (taurine,
asparagine and glycylglycine) are amino acids or amino acid
derivates. Altered levels of amino acids in maternal fluids have
earlier been observed in preeclampsia and fetal growth restriction
[33–37]. Interestingly, they reported a clear association of the
properties of taurine and glycylglycine and the possible pathogen-
esis of PE. In contrast to previous studies performed in the second
and third trimester of pregnancy we did not find any differences in
eicosanoids and oxylipins between PE and controls. However, PE
is a dynamic process, and the metabolic expression profiles may
change during different stages of pregnancy which might explain
why we could not confirm up- or downregulation of any of these
metabolites.
Taurine is a sulfur-containing amino acid-like endogenous
compound found in substantial amounts in mammalian tissues.
Among its many functions, taurine is an important regulator of
antioxidation and membrane stabilization [38]. It is the most
abundant free amino acid –derivative in human placenta [39–40].
Through its cytoprotective role and as a regulator of cell volume,
taurine is thought to be involved in placental trophoblast
development, during the remodeling of the spiral arteries early
in the pregnancy [40]. Reduced activity of taurine transporters in
the placental trophoblast with shortage of taurine in placental
tissue is strongly associated with impaired trophoblast invasion into
the spiral arteries [40]. Impaired placental trophoblast invasion is
Table 3. Selection of the markers significantly different between controls and cases (EO-PE or LO-PE) based on training set.
Type marker Variable p-value FDR MoM ratio case/control
EO-PE
Blood pressure MAP ,0.0001 ,0.0001 1.10
Amine Taurine 0.0015 0.07 0.79
Amine Asparagine 0.0043 0.10 0.84
LO-PE
Blood pressure MAP ,0.0001 ,0.0001 1.07
Amine Glycylglycine 0.0002 0.01 0.72
Student’s t-test was used for statistical analysis. Significance value FDR,15%. EO-PE: early-onset preeclampsia; LO-PE: late-onset preeclampsia; MoM: multiple of the
median; FDR: false discovery rate; MAP: mean arterial pressure.
doi:10.1371/journal.pone.0098540.t003
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one of the most important components of PE pathology [9;17].
Furthermore, taurine has also been associated with cardio- and
vasoprotective effects through the influence of renin-angiotensin-
aldosterone system [38]. From different animal model studies
taurine appears to have antihypertensive effects and to reduce total
peripheral vessel resistance. Spontaneously hypertensive rats
supplemented with taurine show dosage dependant blood pressure
reduction [41]. Taurine supplementation during pregnancy in rats
leads to reduction of hypertension in their offspring as well [41–
43].
Table 4. Model predicted early preeclampsia detection rate (95% CI) for FPR of 10% with prior risk, MAP, taurine, asparagine and
glycylglycine in control and preeclampsia groups.
Training set Test set Validation set
DR at 10% FPR (95% CI) AUC DR at 10% FPR (95% CI) AUC DR at 10% FPR (95% CI) AUC
EO-PE
Prior risk 30 (16–49) 0.74 69 (48–85) 0.92 30 (14–50) 0.73
Prior risk + MAP 55 (37–72) 0.88 81 (58–92) 0.91
Prior risk + taurine 48 (31–66) 0.80 65 (43–82) 0.90
Prior risk + asparagine 36 (22–56) 0.77 70 (48–85) 0.91
Prior risk + MAP + taurine 55 (37–72) 0.88 88 (70–97)* 0.93 55 (36–76) 0.78
Prior risk + MAP + asparagine 55(37–72) 0.87 75 (53–89) 0.91
Prior risk+ MAP + taurine + asparagine 55 (37–72) 0.87 88 (70–97) 0.93
LO-PE
Prior risk 37 (24–53) 0.75 38 (22–55) 0.70 17 (8–35) 0.55
Prior risk + MAP 43 (28–58) 0.81 46 (30–64)* 0.79 17 (8–35) 0.65
Prior risk + glycylglycine 46 (31–60) 0.79 38 (21–59) 0.72
Prior risk + MAP + glycylglycine 53 (37–67) 0.83 42 (27–61) 0.78
DR: detection rate; FPR: false positive rate; MAP: Mean Arterial Pressure; CI: confidence interval; AUC: area under curve, EO-PE: early-onset preeclampsia; LO-PE: late-
onset preeclampsia.
*The best model selected for further validation.
doi:10.1371/journal.pone.0098540.t004
Figure 1. Receiver operating characteristic curves (ROCs) with prediction models for early onset preeclampsia and late onset
preeclampsia used on the validation set. Prior risk of preeclampsia containing maternal characteristics (black line) and prior risk for
preeclampsia combined with different markers (red line). MAP: mean arterial pressure.
doi:10.1371/journal.pone.0098540.g001
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Glycylglycine is a dipeptide of glycine. The latter one appears to
be an essential amino acid in pregnancy and fetal cardiovascular
development since its supplementation prevents elevation of blood
pressure in rats [44]. Furthermore, glycine is an important
component of the S-amino acid metabolic pathway as it
antagonises homocysteine levels [45;46]. Through the biological
feedback loop, lower levels of glycine lead to higher levels of
homocysteine. Hyperhomocysteinemia is a known risk factor for
endothelial dysfunction, PE and, also cardiovascular disease [47–
50].
So far, this is the first study associating lower levels of asparagine
to PE or any other aspect of cardiovascular disease. Although the
role of asparagine in PE development is not yet known, our results
may suggest that the shortage of asparagine may be a risk factor
for development of EO-PE.
All three metabolites are very interesting concerning the
pathophysiology of PE. However, there is still very little known
about the insights of the underlying mechanisms and possible
underlying cause of PE. Due to technical and financial restrictions
we only used two metabolomics platforms (amines and eicosa-
noids/oxylipins) in this study. These two groups are strongly
associated with inflammatory processes in the cell and with
endothelial dysfunctions, which are commonly present in PE
pregnancies [19–26] and therefore likely to reveal relevant
biomarkers. Nevertheless, there are many pathways associated
with the pathogenesis of PE, that would not be reflected here, so
future studies might also explore other metabolic profiles.
None of the significant metabolites that we found have been
brought to light by previous metabolomics studies [13–16]. From
all 105 metabolites we tested, five were reported to be important in
previous studies (methylhistidine, alanine, phenylalanine, methio-
nine and valine). However, in our study these five did not differ
between PE and control groups. There are hardly matches in
significant metabolites selected by different groups [13–16]. This
strengthens the assumption of the major complexity of the
syndrome and the origins of its pathology. The causative complex
of interacting mechanistically blameworthy factors as well as the
likely presence of confounding factors in a system that inherently
changes over time, may therefore lead to differences not only
between two variants of the disease (EO-PE vs LO-PE), but also to
differences between subsets of patient and control cohorts and
even from one study to the next. Reproducibility of results is often
difficult in biomarker studies. Other metabolomics profiling
studies, on cancer for example, face similar difficulties [51–52].
This is mostly due to the fact that samples are taken or
manufactured at different conditions, at different time moments,
or in different populations. This is a shortcoming and a limitation
of this particular method. Therefore, further evaluation of the
metabolites identified in our study should be performed in
different populations.
The prediction model using a combination of prior risk with
MAP and taurine provided a DR of 55% at a fixed 10% FPR in
the case of EO-PE, which is comparable to the results, obtained in
training. Addition of asparagine did not further improve the results
(Table 4). For LO-PE a model using prior risk performed best and
it gave a DR of 15% on the validation set. Addition of MAP did
not improve the DR, however the AUC increased. Glycylglycine,
although significantly decreased in LO-PE versus controls
(Table 3), did not turn out to be sufficiently additionally
informative to become included in the final prediction model.
Therefore, taurine remains the single predictive metabolite marker
of this study. Because of its narrow affiliation with placentation,
hypertension and cardiovascular disease, a potential screening role
of taurine is conceivable.
Ideally, a biomarker for PE should be predictive throughout the
entire first trimester. However, due to different processes that are
involved in early pregnancy and placentation other biomarkers
might be predictive at different gestational weeks. Most of our
samples were taken after 11 weeks of gestation; a subanalysis of our
data indicated that the metabolites identified in this study were still
found in samples from 11 weeks onwards only (data not shown).
We chose not to combine the metabolites with classical first-
trimester screening markers such as Pregnancy Associated Plasma
Protein-A (PAPP-A), A Disintegrin And Metalloprotease 12
(ADAM12), Placental Protein 13 (PP13), Placental Growth Factor
(PlGF). Given our results, it is plausible that the DR of PE would
increase if taurine would be added, although the added value in
such a large-scale screening setting, also in relation to increased
costs and logistics, would need to be established in a larger
population before further recommendations can be made. Until
such validation studies have been carried out our results should be
considered preliminary.
In conclusion, three markers out of 105 were significantly
different between women who developed PE and healthy
individuals, but after adequate statistical analysis only taurine
remained as a predictive marker in the screening model. However,
given the possible role of taurine in hypertension treatment, its role
as a possible screening marker or maybe even as a diet supplement
early in pregnancy remains very interesting.
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